title: Lysophosphatidic acid and ovarian cancer: a paradigm for tumorogenesis and patient management.
authors.affiliation: Atairgin Technologies, Irvine, CA 92612 USA.
authors.forename: J R
authors.initials: JR
authors.lastname: Erickson
authors.forename: Y
authors.initials: Y
authors.lastname: Hasegawa
authors.forename: X
authors.initials: X
authors.lastname: Fang
authors.forename: A
authors.initials: A
authors.lastname: Eder
authors.forename: M
authors.initials: M
authors.lastname: Mao
authors.forename: T
authors.initials: T
authors.lastname: Furui
authors.forename: J
authors.initials: J
authors.lastname: Aoki
authors.forename: A
authors.initials: A
authors.lastname: Morris
authors.forename: G B
authors.initials: GB
authors.lastname: Mills
mesh_terms: D023102:Anoikis; D002471:Cell Transformation, Neoplastic; D005260:Female; D006801:Humans; D008246:Lysophospholipids / Q000097:blood / Q000378:metabolism* / Q000494:pharmacology; D008954:Models, Biological; D009361:Neoplasm Invasiveness; D010051:Ovarian Neoplasms / Q000209:etiology* / Q000628:therapy*; D010053:Ovary / Q000187:drug effects; D015398:Signal Transduction
chemical_list: D008246:Lysophospholipids